Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L

BACKGROUND: An increasing number of studies is now devoted to immunotherapy of cancer. We evaluated the clinical benefit of hepcortespenlisimut-L (Hepko-V5 [formerly known as V5])—an oral therapeutic vaccine designated by the United States Food and Drug Administration (FDA) as an orphan drug for tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Tarakanovskaya, Marina G, Chinburen, Jigjidsuren, Batchuluun, Purev, Munkhzaya, Chogsom, Purevsuren, Genden, Dandii, Dorjiin, Hulan, Tsogkhuu, Oyungerel, Dandii, Kutsyna, Galyna A, Reid, Alan A, Borisova, Vika, Bain, Allen I, Jirathitikal, Vichai, Bourinbaiar, Aldar S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396941/
https://www.ncbi.nlm.nih.gov/pubmed/28443252
http://dx.doi.org/10.2147/JHC.S122507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396941/
https://www.ncbi.nlm.nih.gov/pubmed/28443252
http://dx.doi.org/10.2147/JHC.S122507

Ejemplares similares